Pseudoephedrine/loratadine

Pseudoephedrine/loratadine
Combination of
Pseudoephedrine	Sympathomimetic
Loratadine	H₁ antagonist
Clinical data
Trade names	Claritin-D, Clarinase
AHFS/Drugs.com	entry
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	Oral
Legal status
Legal status	US: OTC
Identifiers
ATC code	R01BA52 (WHO)
(verify)

Pseudoephedrine/loratadine (trade names Claritin-D, Clarinase, Clarinase Repetabs, Lorinase) is an orally administered combination drug used for the treatment of allergic rhinitis and the common cold. This drug can be bought "over the counter".

Pseudoephedrine, one of the naturally occurring alkaloids of ephedra, is a sympathomimetic used as a decongestant. It produces a decongestant effect that facilitates vasoconstriction and the shrinkage of congested mucosa in upper respiratory areas.
Loratadine is a long-acting antihistamine (H₁ histamine antagonist) that is less sedating than older substances of its type.

Medical uses

Pseudoephedrine/loratadine are indicated for the relief of symptoms associated with allergic rhinitis and the common cold including nasal congestion, sneezing, rhinorrhea, pruritus and lacrimation.

Composition

Clarinase Repetabs

A Clarinase Repetab tablet contains 5 mg loratadine in the tablet coating and 120 mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core. The two active components in the coating are quickly liberated; release of pseudoephedrine in the core is delayed for several hours.

Interactions, adverse effects and contraindications

Interactions, adverse effects and contraindications are described in more detail in the articles about pseudoephedrine and loratadine.

Interactions

When sympathomimetics are given to patients receiving monoamine oxidase inhibitors (MAO inhibitors), hypertensive reactions, including hypertensive crises may occur.

Adverse effects

During controlled clinical studies with the recommended dosage, the incidence of adverse effects was comparable to that of placebo, with the exception of insomnia and dry mouth, both of which were commonly reported.

Contraindications

Clarinase is contraindicated in patients receiving MAO inhibitor therapy or within 14 days of discontinuing such treatment and in patients with narrow angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease and hyperthyroidism.

References

Drugs.com: Claritin-D
Israel Ministry of Health: Clarinase Repetabs
Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X.

Decongestants and other nasal preparations (R01)

Topical

Sympathomimetics, plain	Cyclopentamine Ephedrine Epinephrine Fenoxazoline Levomethamphetamine Metizoline Naphazoline Oxymetazoline Phenylephrine Propylhexedrine Tetryzoline Tramazoline Tuaminoheptane Tymazoline Xylometazoline

Antiallergic agents, excluding corticosteroids	Spaglumic acid histamine antagonists (Levocabastine Antazoline Thonzylamine) mast cell stabilizer (some are also antihistamines) (Cromoglicic acid Nedocromil Azelastine Olopatadine Lodoxamide)

Corticosteroids	Beclometasone dipropionate Betamethasone Budesonide Ciclesonide Dexamethasone Flunisolide Fluticasone Mometasone furoate Prednisolone Tixocortol Triamcinolone

Other nasal preparations	Cafaminol Calcium hexamine thiocyanate Eucalyptus oil Framycetin Hexamidine Hyaluronan Ipratropium bromide Mupirocin Retinol Ritiometan Saline water

Systemic use:
Sympathomimetics

This article is issued from Wikipedia - version of the Friday, April 01, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.